"Legal Highs" - An emerging epidemic of novel psychoactive substances

International Review of Neurobiology

Volumn 120, Issue , 2015, Pages 273-300

  Zawilska, Jolanta B ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF MEDICAL BIOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CANNABINOID DERIVATIVE; ILLICIT DRUG; OPIATE; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; CANNABINOID; CENTRAL STIMULANT AGENT;

BEHAVIOR; COGNITION; DEATH; DRUG ABUSE; DRUG CLASSIFICATION; DRUG EFFECT; DRUG INTOXICATION; DRUG METABOLISM; DRUG USE; EMERGENCY; HUMAN; LAW; LEGAL ASPECT; MOOD; NONHUMAN; ONLINE SYSTEM; PREVALENCE; PRIORITY JOURNAL; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; SUBSTANCE-RELATED DISORDERS;

ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; MOLECULAR STRUCTURE; SUBSTANCE-RELATED DISORDERS;

EID: 84943354956     PISSN: 00747742     EISSN: 21625514     Source Type: Book Series    
DOI: 10.1016/bs.irn.2015.02.009     Document Type: Chapter

References (116)

1. Aarde, S. M., Angrish, D., Barlow, D. J., Wright, M. J., Jr., Vandewater, S. A., Creehan, K. M., et al. (2013). Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addiction Biology, 18, 786-799.
2. Aarde, S. M., Huang, P. K., Creehan, K. M., Dickerson, T. J., Taffe, M. A. (2013). The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: Self-administration and locomotor activity in rats. Neuropharmacology, 71, 130-140.
3. Advisory Council on the Misuse of Drugs (ACMD). (2013). "NBOMe" compounds: a review of the evidence of use and harm. Available at https://www.gov.uk./ goverment/uploads/system/uploads/attachment_data/file/204808/J_TCDP_report_ on_5-6APB_and_NBOMe_compounds.pdf. Retrieved October 17th, 2014.
4. Antia, U., Lee, H. S., Kydd, R. R., Tingle, M. D., Russell, B. R. (2009). Pharmacokinetics of 'party pill' N-benzylpiperazine (BZP) in healthy human participants. Forensic Science International, 186, 63-67.
5. Antia, U., Tingle, M. D., Russell, B. R. (2009). Metabolic interactions with piperazinebased 'party pills'. Journal of Pharmacy and Pharmacology, 61, 877-882.
6. Araú jo, A. M., Valente, M. J., Carvalho, M., Dias da Silva, D., Gaspar, H., Carvalho, F., et al. (2014). Raising awareness of new psychoactive substances: Chemical analysis and in vitro toxicity screening of 'legal high' packages containing synthetic cathinones. Archives of Toxicology. http://dx.doi.org/10.1007/s00204-014-1278-7.
7. Aung, M. M., Griffin, G., Huffman, J. W., Wu, M., Keel, C., Yang, B., et al. (2000). Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug and Alcohol Dependence, 60, 133-140.
8. Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., Ferreiró s, N. (2009). 'Spice' and other herbal blends: Harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry, 44, 832-837.
9. Barratt, M. J., Cakic, V., Lenton, S. (2013). Patterns of synthetic cannabinoid use in Australia. Drug and Alcohol Review, 32, 141-146.
10. Baumann, M. H., Partilla, J. S., Lehner, K. R., Thorndike, E. B., Hoffman, A. F., Holy, M., et al. (2013). Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology, 38, 552-562.
11. Bebarta, V. S., Ramirez, S., Varney, S. M. (2012). Spice: A new "legal" herbal mixture abused by young active duty military personel. Substance Abuse, 33, 191-194.
12. Bonar, E. E., Ashrafioun, L., Illgen, M. A. (2014). Synthetic cannabinoid use among patients in residential substance use disorder treatment: Prevalence, motives, and correlates. Drug and Alcohol Dependence, 143, 268-271.
13. Bosak, A., LoVecchio, F., Levine, M. (2013). Recurrent seizures and serotonin syndrome following "2C-I" ingestion. Journal of Medical Toxicology, 9, 196-199.
14. Brennan, K., Johnstone, A., Fitzmaurice, P., Lea, R., Schenk, S. (2007). Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and crosssensitization to methamphetamine (MA). Drug and Alcohol Dependence, 88, 204-213.
15. Brents, L. K., Gallus-Zawada, A., Radominska-Pandya, A., Vasiljevik, T., Prisinzano, T. E., Fantegrossi, W. E., et al. (2012). Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochemical Pharmacology, 83, 952-961.
16. Brunt, T. M., Poortman, A., Niesink, R. J., van den Brink, W. (2011). Instability of the ecstasy market and a new kid on the block: Mephedrone. Journal of Psychopharmacology, 25, 1543-1547.
17. Buttler, R. A., Sheridan, J. L. (2007). Highs and lows: Patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand. Harm Reduction Journal, 4, 18.
18. Carroll, F. I., Lewin, A. H., Mascarella, S. W., Seltzman, H. H., Reddy, P. A. (2012). Designer drugs: A medicinal chemistry perspective. Annals of the New York Academy of Sciences, 1248, 18-38.
19. Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., Huestis, M. A. (2014). Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 144, 12-41.
20. Chen, C., Kostakis, C., Irvine, R. J., White, J. M. (2013). Increases in use of novel synthetic stimulant are not directly linked to decreased use of 3,5-methylenedioxy- N-methylamphetamine (MDMA). Forensic Science International, 231, 278-283.
21. Coppola, M., Mondola, R. (2013). 5-Iodo-2-aminoindan (5-IAI): Chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects. Toxicology Letters, 218, 24-29.
22. Corazza, O., Demetrovics, Z., van den Brink, W., Schifano, F. (2013). 'Legal highs' an inappropriate term for 'Novel Psychoactive Drugs' in drug prevention and scientific debate. The International Journal on Drug Policy, 24, 82-83.
23. Corazza, O., Valeriani, G., Bersani, F. S., Corkery, J., Martinotti, G., Bersani, G., et al. (2014). "Spice," "kryptonite," "black mamba": An overview of brand names and marketing strategies of novel psychoactive substances on the web. Journal of Psychoactive Drugs, 46, 287-294.
24. Corkery, J. M., Elliott, S., Schifano, F., Corazza, O., Ghodse, A. H. (2012). 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): A preliminary review. Progress in Neuropsychopharmacology and Biological Psychiatry, 39, 253-258.
25. Corkery, J. M., Elliott, S., Schifano, F., Corazza, O., Ghodse, A. H. (2013). MDAI (5,6-methylenedioxy-2-aminoindane 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6- amine 'sparkle'; 'mindy') toxicity: A brief overview and update. Human Psychopharmacology: Clinical and Experimental, 28, 345-355.
26. Corkery, J. M., Schifano, F., Ghodse, A. H. (2012). Mephedrone-related fatalities in the United Kingdom: Contextual, clinical and practical issues. Pharmacology, 17, 355-380. Available at: http://cdn.intechopen.com/pdfs/32134/InTech-Mephedrone_related_ fatalities_in_the_united_kingdom_contextual_clinical_and_practical_issues.pdf, Retrieved December 9, 2012.
27. Cosbey, S. H., Peters, K. L., Quinn, A., Bentley, A. (2013). Mephedrone (methylmethcathinone) in toxicology casework: A Northern Ireland perspective. Journal of Analytical Toxicology, 37, 74-82.
28. Dean, B. V., Stellpflug, S. J., Burnett, A. M., Engebretsen, K. M. (2013). 2C or not 2C: Phenethylamine designer drug review. Journal of Medical Toxicology, 9, 172-178.
29. Deluca, P., Davey, Z., Corazza, O., Di Furia, L., Farre, M., Flesland, L. H., et al. (2012). Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Progress in Neuropsychopharmacology and Biological Psychiatry, 39, 221-226.
30. Dorairaj, J. J., Healy, C., McMenamin, M., Eadie, P. A. (2012). The untold truth about "bath salt" highs: A case series demonstrating local tissue injury. Journal of Plastic, Reconstructive & Aesthetic Surgery, 65, e37-e41.
31. Drees, J. C., Stone, J. A., Wu, A. H. (2009). Morbidity involving the hallucinogenic designer amines MDA and 2C-I. Journal of Forensic Sciences, 54, 1485-1487.
32. Dresen, S., Ferreiró s, N., Pütz, M., Westphal, F., Zimmermann, R., Auwärter, V. (2010). Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. Journal of Mass Spectrometry, 45, 1186-1194.
33. Elliott, S., Evans, J. (2014). A 3-year review of new psychoactive substances in casework. Forensic Science International, 243, 55-60.
34. EMCDDA. (2011). Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances. Available at: http://www.emcdda.europa.eu/ attachements.cfm/att_116646_EN_TDAK11001ENC_WEB-OPTIMISED%20FILE. pdf, Retrieved November 21, 2014.
35. EMCDDA. (2012). Annual report 2012. The state of the drug problem in Europe. Available at: http://www.emcdda.europa.eu/attachments.cfm./att_190854_EN_TDAC13001ENC_ pdf, Retrieved June 9, 2014.
36. EMCDDA. (2013).EUdrug markets reports. Astrategic analysis.Available at: http://www.emcdda. europa.eu/publications/joint-publications/drug-markets, Retrieved June 9, 2014.
37. EMCDDA. (2014a). European drug report 2014. Trends and developments. Available at: http:// www.emcdda.europa.eu/attachements.cfm/att_228272_EN_TDAT14001ENN.pdf, Retrieved October 22, 2014.
38. EMCDDA. (2014b). EMCDDA-Europol joint report on a new psychoactive substance:MDPV (3,4- methylenedioxypyrovalerone). Available at: http://www.emcdda.europa.eu/attachements. cfm/att_222592_EN_TDAS14001ENN.%20pdf, Retrieved October 22, 2014.
39. EMCDDA. (2014c). EMCDDA-Europol joint report on a new psychoactive substance: 5-(2- aminopropyl)indole. Available at: http://www.emcdda.europa.eu/attachements.cfm/att_ 194430_EN_TDAS13001ENN.pdf, Retrieved October 16, 2014.
40. 9-THC: Mechanism underlying greater toxicity? Life Sciences, 97, 45-54.
41. Fantegrossi, W. E., Winger, G., Woods, J. H., Woolverton, W. L., Coop, A. (2005). Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug and Alcohol Dependence, 77, 161-168.
42. Fattore, L., Fratta, W. (2011). Beyond THC: The new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience, 5, 60.
43. Forrester, M. B., Kleinschmidt, K., Schwarz, E., Young, A. (2012). Synthetic cannabinoid and marijuana exposures reported to poison centers. Human & Experimental Toxicology, 31, 1006-1011.
44. Gallagher, C. T., Assi, S., Stair, J. L., Fergus, S., Corazza, O., Corkery, J. M., et al. (2012). 5,6-Methylenedioxy-2-aminoindane: From laboratory curiosity to 'legal high'. Human Psychopharmacology: Clinical and Experimental, 27, 106-112.
45. Gee, P., Richardson, S., Woltersdorf, W., Moore, G. (2005). Toxic effects of BZP-based herbal party pills in humans: A prospective in Christchurch, New Zealand. New Zealand Medical Journal, 118, U1784.
46. Gibbons, S. (2012). 'Legal highs'-Novel and emerging psychoactive drugs: A chemical overview for the toxicologist. Clinical Toxicology (Philadelphia, Pa), 50, 15-24.
47. 9-Tetrahydrocannabinol-like discriminative stimulus effects in monkeys. Journal of Pharmacology and Experimental Therapeutics, 340, 37-45.
48. Gregg, R. A., Rawls, S. M. (2014). Behavioral pharmacology of designer cathinones: A review of the preclinical literature. Life Sciences, 97, 27-30.
49. Gunderson, E. W., Haughey, H. M., Ait-Daoud, N., Joshi, A. S., Hart, C. L. (2014). A survey of synthetic cannabinoid consumption by current cannabis users. Substance Abuse, 35, 184-189.
50. Hartman, R. L., Huestis, M. A. (2013). Cannabis effects on driving skills. Clinical Chemistry, 59, 478-492.
51. Helander, A., Bäckberg, M., Hultén, P., Al-Saffar, Y., Beck, O. (2014). Detection of new psychoactive substance use among emergency room patients: Results from the Swedish STRIDA project. Forensic Science International, 243, 23-29.
52. Heltsley, R., Shelby, M. K., Crouch, D. J., Black, D. L., Robert, T. A., Marshall, L., et al. (2012). Prevalence of synthetic cannabinoids in US athletes: Initial findings. Journal of Analytical Toxicology, 36, 588-593.
53. Hu, X., Primack, B. A., Barnett, T. E., Cook, R. L. (2011). College students and use of K2: An emerging drug of abuse in young persons. Substance Abuse Treatment, Prevention, and Policy, 6, 16.
54. Hudson, S., Ramsey, J. (2011). The emergence and analysis of synthetic cannabinoids. Drug Testing and Analysis, 3, 466-478.
55. Hunter, L. J., Dargan, P. I., Benzie, A., White, J. A., Wood, D. M. (2014). Recreational drug use in men who have sex with men (MSM) attending UK sexual health services is significantly higher than in non-MSM. Postgraduate Medical Journal, 90, 133-138.
56. Johnson, P. S., Johnson, M. W. (2014). Investigation of "Bath Salts" use pattern within an online sample of users in the United States. Journal of Psychoactive Drugs, 46, 369-378.
57. Johnson, L. A., Johnson, R. L., Portier, R. B. (2013). Current "Legal highs" Journal of Emergency Medicine, 44, 1108-1115.
58. Katselou, M., Papoutsis, I., Nikolaou, P., Spiliopoulou, C., Athanaselis, S. (2014). 5-(2- aminopropyl)indole: A new player in the drama of 'legal highs' alerts the community. Drug and Alcohol Review, 34, 51-57.
59. King, L. A. (2014). New phenethylamines in Europe. Drug Testing and Analysis, 6, 808-818.
60. Kronstrand, R., Roman, M., Dahlgren, M., Thelander, G., Wikström, M., Druid, H. (2013). A cluster of deaths involving 5-(2-aminopropyl)indole (5-IT). Journal of Analytical Toxicology, 37, 542-546.
61. Loeffler, G., Hurst, D., Penn, A., Yung, K. (2012). Spice, bath salts, and the U.S. military: The emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces. Military Medicine, 177, 1041-1048.
62. Maxwell, J. C. (2014). Psychoactive substances-Some new, some old: A scan of the situation in the U.S. Drug and Alcohol Dependence, 134, 71-77.
63. McElrath, K., O'Neill, C. (2011). Experiences with mephedrone pre- and post-legislative control: Perceptions of safety and sources of supply. International Journal on Drug Policy, 22, 120-127.
64. McGraw, M., McGraw, L. (2012). Bath salts: Not as harmless as they sound. Journal of Emergency Nursing, 38, 582-588.
65. Meyer, M. R., Du, P., Schuster, F., Maurer, H. H. (2010). Studies on the metabolism of the a-pyrrolidinophenone designer drug methylenedioxypyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-highresolution MS and its detectability in urine by GC-MS. Journal of Mass Spectrometry, 45, 1426-1442.
66. Meyer, M. R., Maurer, H. H. (2010). Metabolism of designer drugs of abuse: An updated review. Current Drug Metabolism, 11, 461-482.
67. Meyer, M. R., Vollmar, C., Schwaninger, A. E., Wolf, E., Maurer, H. H. (2012). New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoro-methcathinone: Studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC- high-resolution MS and their detectability in urine. Journal of Mass Spectrometry, 47, 253-262.
68. Meyer, M. R., Wilhelm, J., Peters, F. T., Maurer, H. H. (2010). Beta-keto amphetamines: Studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry, 397, 1225-1233.
69. Möller, I., Wintermeyer, A., Bender, K., Jübner, M., Thomas, A., Krug, O., et al. (2011). Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Testing and Analysis, 3, 609-620.
70. Monteiro, M. S., Bastos, Mde L., Guedes de Pinho, P., Carvalho, M. (2013). Update on 1-benzylpiperazine (BZP) party pills. Archives of Toxicology, 87, 929-947.
71. Moore, K., Dargan, P. I., Wood, D. M., Measham, F. (2013). Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine. European Addiction Research, 19, 276-283.
72. Motbey, C. P., Hunt, G. E., Bowen, M. T., Artissm, S., McGregor, I. S. (2012). Mephedrone (4-methylmethcathinone, 'meow'): Acute behavioural effects and distribution of Fos expression in adolescent rats. Addiction Biology, 17, 409-422.
73. Musselman, M. E., Hampton, J. P. (2014). "Not for human consumption": A review of emerging designer drugs. Pharmacotherapy, 34, 745-757.
74. Musshoff, F., Madea, B., Kernbach-Wighton, G., Bicker, W., Kneisel, S., Hutter, M., et al. (2014). Driving under the influence of synthetic cannabinoids ("Spice"): A case series. International Journal of Legal Medicine, 128, 59-64.
75. Paillet-Loilier, M., Cesbon, A., Le Boisselier, R., Jourgine, J., Debruyene, D. (2014). Emerging drugs of abuse: Current perspectives on substituted cathinones. Substance Abuse and Rehabilitation, 5, 37-52.
76. Papanti, D., Schifano, F., Botteon, G., Bertossi, F., Mannix, J., Vidoni, D., et al. (2013). "Spiceophrenia": A systematic overview of "spice"-related psychopathological issues and a case report. Human Psychopharmacology: Clinical and Experimental, 28, 379-389.
77. Papaseit, E., Farré, M., Schifano, F., Torrens, M. (2014). Emerging drugs in Europe. Current Opinion in Psychiatry, 27, 243-250.
78. Pedersen, A. J., Petersen, T. H., Linnet, K. (2013). In vitro metabolism and pharmacokinetic studies on methylone. Drug Metabolism and Disposition, 41, 1247-1255.
79. Pedersen, A. J., Reitzel, L. A., Johansen, S. S., Linnet, K. (2013). In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Testing and Analysis, 5, 430-438.
80. Pertwee, R. G. (2005). Pharmacological action of cannabinoids. Handbook of Experimental Pharmacology, 168, 1-51.
81. Presley, B. C., Jansen-Varnum, S. A., Logan, B. K. (2013). Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings. Forensic Science Review, 25, 27-46.
82. Rojek, S., Klys, M., Maciów-Glab, M., Kula, K., Strona, S. (2014). Cathinones derivatives-related deaths as exemplified by two fatal cases involving methcathinone with 4-methylmethcathinone and 4-methylethcathinone. Drug Testing and Analysis, 6, 770-777.
83. Russo, R., Marks, N., Morris, K., King, H., Gelvin, A., Rooney, R. (2012). Life-treating necrotizing fasciitis due to "bath salts" injection. Orthopedics, 25, e124-e127.
84. Sacks, J., Ray, M. J., Williams, S., Opatowsky, M. J. (2012). Fatal toxic leukoencephalopathy secondary to overdose of a new psychoactive designer drug 2C-E ("Europe"). Proceedings (Baylor University. Medical Center), 25, 374-376.
85. Schifano, F., Albanese, A., Fergus, S., Stair, J. L., Deluca, P., Corazza, O., et al. (2011). Mephedrone (4-methylmethcathinone, 'meow meow'): Chemical, pharmacological and clinical issues. Psychopharmacology (Berlin), 214, 593-602.
86. Seetohul, L. N., Pounder, D. J. (2013). Four fatalities involving 5-IT. Journal of Analytical Toxicology, 37, 447-451.
87. Shortall, S. E., Macerola, A. E., Swaby, R. T., Jayson, R., Korsah, C., Pillidge, K. E., et al. (2013). Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. European Neuropsychopharmacology, 23, 1085-1095.
88. Simmler, L. D., Buser, T. A., Donzelli, M., Schramm, Y., Dieu, L. H., Huwyler, J., et al. (2013). Pharmacological characterization of designer cathinones in vitro. British Journal of Pharmacology, 168, 458-470.
89. Simmler, L. D., Rickli, A., Schramm, Y., Hoener, M. C., Liechti, M. E. (2014). Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochemical Pharmacology, 88, 237-244.
90. Smith, C. D., Robert, S. (2014). 'Designer drugs': Update on the management of novel psychoactive substance misuse in the acute care setting. Clinical Medicine, 14, 409-415.
91. Spiller, H. A., Ryan, M. L., Weston, R. G., Jansen, J. (2011). Clinical experience with analytic confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clinical Toxicology (Philadelphia, Pa.), 49, 499-505.
92. Strano-Rossi, S., Cadwallader, A. B., de la Torre, X., Botre, F. (2010). Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry, 24, 2706-2714.
93. Stuart, D. (2013). Sexualised drug use by MSM: Background, current status and response. HIV Nursing Journal, 13, 6-10.
94. Tekulve, K., Alexander, A., Tormoehlen, L. (2014). Seizures associated with synthetic cathinone exposures in the pediatric population. Pediatric Neurology, 51, 67-70.
95. Teske, J.,Weller, J. P., Fieguth, A.,Rothämel,T., Schulz, Y., Tröger,H.D. (2010). Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1- pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatographytandem mass spectrometry. Journal of Chromatography B, 878, 2659-2663.
96. Tuv, S. S., Krabseth, H., Karinen, R., Olsen, K. M., Øiestad, E. L., Vindenes, V. (2014). Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period. Accident Analysis and Prevention, 62, 26-31.
97. United Nations Office on Drugs and Crime (UNODC). (2013). Worlds drug report 2013. New psychoactive substances: Concepts and definitions, Vienna, pp. 60-115. Available at: http://www.unodc.org/unodc/secured/wdr/wdr2013/World_Drug_Report_2013.pdf. Accessed September 22, 2014.
98. Van Hout, M. C., Bingham, T. (2012). "A costly turn on": Patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. The International Journal on Drug Policy, 23, 188-197.
99. Vandrey, R., Dunn, K. E., Fry, J.A.,Girling, E. R. (2012). A survey study to characterize use of Spice products (synthetic cannabinoids). Drug and Alcohol Dependence, 120, 238-241.
100. 9-tetrahydrocannabinol (THC) in C57Bl/6J mice. European Journal of Pharmacology, 615, 102-107.
101. Vardakou, I., Pistos, C., Spiliopoulou, C. (2010). Spice drugs as a new trend: Mode of action, identification and legislation. Toxicology Letters, 197, 157-162.
102. Watterson, L. R., Watterson, E., Olive, M. F. (2013). Abuse liability of novel 'legal high' designer stimulants: Evidence from animal models. Behavioral Pharmacology, 24, 341-355.
103. Wiebelhaus, J. M., Poklis, J. L., Poklis, A., Vann, R. E., Lichtman, A. H., Wise, L. E. (2012). Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice. Drug and Alcohol Dependence, 126, 316-323.
104. Wiley, J. L., Marusich, J. A., Huffman, J. W. (2014). Moving around the molecule: Relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sciences, 97, 55-63.
105. Winstock, A. R., Barratt, M. J. (2013). Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and Alcohol Dependence, 131, 106-111.
106. Wood, D. M., Button, J., Lidder, S., Ramsey, J., Holt, D. W., Dargan, P. I. (2008). Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperazine (BZP). Journal of Medical Toxicology, 4, 254-257.
107. Wood, D. M., Dargan, P. I. (2012). Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP). Clinical Toxicology (Philadelphia, Pa.), 50, 727-732.
108. Wood, D. M., Puchnarewicz, M., Johnston, A., Dargan, P. I. (2012). A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity. European Journal of Clinical Pharmacology, 68, 349-353.
109. Yarosh, H. L., Katz, E. B., Coop, A., Fantegrossi, W. E. (2007). MDMA-like behavioral effects of N-substituted piperazines in the mouse. Pharmacology, Biochemistry, and Behavior, 88, 18-27.
110. Yeakel, J. K., Logan, B. K. (2013). Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. Journal of Analytical Toxicology, 37, 547-551.
111. Zawilska, J. B. (2011). "Legal highs"-New players in the old drama. Current Drug Abuse Reviews, 4, 123-130.
112. Zawilska, J. B. (2014). Mephedrone and other cathinones. Current Opinion in Psychiatry, 27, 256-262.
113. Zawilska, J. B., Wojcieszak, J. (2013). Designer cathinones-An emerging class of novel recreational drugs. Forensic Science International, 231, 42-53.
114. Zawilska, J. B., Wojcieszak, J. (2014). Spice/K2 drugs: More than innocent substitutes for marijuana. International Journal of Neuropsychopharmacology, 17, 509-525.
115. Zuba, D., Byrska, B. (2013). Prevalence and co-existence of active components of 'legal highs'. Drug Testing and Analysis, 5, 420-429.
116. Zuba, D., Byrska, B., Maciow, M. (2011). Comparison of "herbal highs" composition. Analytical and Bioanalytical Chemistry, 400, 119-126.